US Stock MarketDetailed Quotes

URGN UroGen Pharma Ltd

Watchlist
  • 10.770
  • +0.230+2.18%
Close Feb 14 16:00 ET
  • 11.480
  • +0.710+6.59%
Post 20:01 ET
454.49MMarket Cap-3.57P/E (TTM)

About UroGen Pharma Ltd Company

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

Company Profile

SymbolURGN
Company NameUroGen Pharma Ltd
Listing DateMay 4, 2017
Issue Price13.00
Founded2004
CEOMs. Elizabeth Barrett
MarketNASDAQ
Employees201
Fiscal Year Ends12-31
Address400 Alexander Park Drive,4th floor
CityPrinceton
ProvinceNew Jersey
CountryUnited States of America
Zip Code08540
Phone1-646-768-9780

Company Executives

  • Name
  • Position
  • Salary
  • Elizabeth Barrett
  • Director, President and Chief Executive Officer
  • 4.64M
  • Jason Drew Smith
  • General Counsel, Chief Compliance Officer and Corporate Secretary
  • 1.51M
  • Dr. Mark P. Schoenberg, M.D.
  • Chief Medical Officer
  • 1.36M
  • Christopher Degnan
  • Chief Financial Officer and Principal Accounting Officer
  • --
  • Dr. Arie S. Belldegrun, F.A.C.S.,M.D.
  • Chairman of the Board
  • 342.18K
  • Dr. Stuart Holden, M.D.
  • Independent Director
  • 201.53K
  • Dr. Leana S. Wen, M. Sc.,M.D.
  • Independent Director
  • 194.41K
  • Cynthia M. Butitta
  • Independent Director
  • 204.06K
  • James A. Robinson, Jr
  • Independent Director
  • 313.29K
  • Daniel George Wildman
  • Independent Director
  • 192.72K

Trending Stocks

Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Big Tech’s earnings season in full swing! Nvidia is the only one left
On Thursday, $Amazon (AMZN.US)$ stock fell after the firm reported Q4 adjusted earnings of $1.86/share, vs estimates of $1.50/share, on reve Show More